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Introduction {#sec005}
============

Warfarin is the most commonly prescribed oral anticoagulant in resource-limited settings, where it is used for the treatment and prophylaxis of venous thromboembolism, and for the prevention of embolic strokes in patients with atrial fibrillation (AF) and valvular heart disease. Patients receiving warfarin require ongoing monitoring of their International Normalised Ratio (INR) which needs to be kept in a defined therapeutic range determined by the indication for therapy. Under-dosing (leading to a sub-therapeutic INR) and overdosing (leading to a supra-therapeutic INR) places individuals at risk of thrombosis and bleeding, respectively. INR control in patients in sub-Saharan Africa is often poor \[[@pone.0227458.ref001]--[@pone.0227458.ref003]\] which may result in potentially preventable morbidity \[[@pone.0227458.ref004]\] and mortality \[[@pone.0227458.ref005]\]. The burden of HIV and tuberculosis (TB) is high in sub-Saharan Africa \[[@pone.0227458.ref006]\]. Patients on warfarin who are HIV positive and/or have TB require multiple concomitant medicines, which may interact with warfarin and complicate warfarin dosing and dose adjustment \[[@pone.0227458.ref007]\].

In high income countries, warfarin dosing is frequently guided by validated dosing algorithms, some of which include genotyping for polymorphisms important for warfarin metabolism \[[@pone.0227458.ref008]\]. Little work has been done on validated algorithms to guide dosing in sub-Saharan Africa. Direct oral anticoagulants (DOACs) are widely accessible in high-income settings, but higher costs limit their use in resource-limited settings. Warfarin is therefore likely to continue to be used extensively, and strategies to improve anticoagulation control on warfarin are important.

Our aim was to evaluate the quality of anticoagulation services in Uganda and South Africa and to describe the clinical and demographic characteristics of patients receiving warfarin.

Materials and methods {#sec006}
=====================

Study design and sites {#sec007}
----------------------

We conducted the audit between 1 January and 31 July 2018. We included two outpatient clinics in Kampala, Uganda: at Mulago National Referral Hospital, and at the Uganda Heart Institute (UHI), which is a specialized cardiac centre. In South Africa, we included clinics providing outpatient anticoagulation care at Groote Schuur Hospital, Tygerberg Hospital, and Gugulethu Community Health Centre. All audited clinics were located in an urban setting. In Uganda, both clinics were located in referral hospitals where the vast majority of patients receiving warfarin anticoagulation in the country are managed. The clinics in Cape Town, South Africa, represented primary, secondary and tertiary levels of care.

We collected information from key members of clinic staff including doctors, nurses, laboratory and pharmacy staff using a structured data capture sheet. Data collected included availability and cost of anticoagulation drugs, and INR measurement and availability and use of dose adjustment protocols (see [S1 Data](#pone.0227458.s002){ref-type="supplementary-material"}).

We reviewed a sample of patients' clinic records. The method of sampling clinic records varied between clinic sites because of difference in systems for record storage and documentation of clinic attendance. We aimed to minimise sampling bias. However, none of the included anticoagulation clinics had a readily available sampling frame that included all the patients in care at that clinic. We therefore could not draw a truly random sample of patients in care at any of the clinics. We extracted demographic data and clinical data including indication for anticoagulation, comorbidities, concomitant medications and INR results over the six months prior to the most recent clinic visit (see [S1 Data](#pone.0227458.s002){ref-type="supplementary-material"})

We did not perform a formal sample size calculation as this was a descriptive audit of service provision, and as we did not want to test a hypothesis or estimate a parameter with a certain level of precision. We aimed to review at least 200 clinical records as this was considered feasible.

Data analysis {#sec008}
-------------

Qualitative data were summarised using tables with descriptive text, and quantitative data expressed as summary statistics--median and interquartile range (IQR). We calculated time in therapeutic range (TTR) over the most recent three months using the Rosendaal interpolation method \[[@pone.0227458.ref009]\]. We did not place any restriction on the maximum interval between INR measurements when applying the method.

We identified concomitant drugs that could interact with warfarin using Stockley's Drug Interactions \[[@pone.0227458.ref010]\].

We used Stata 15.1 (StataCorp, College Station, Texas, USA) and R software package 3.5.3 for statistical analysis and figure generation.

Ethical approvals {#sec009}
-----------------

The Joint Clinical Research Centre and Uganda National Council for Science and Technology in Uganda (HS 179ES) and the Human Research Ethics Committee at the Faculty of Health Sciences of the University of Cape Town in South Africa (585/2017) gave ethics approval. We obtained institutional clearance for the audited clinics. All staff providing information in Uganda provided written informed consent prior to participation. In South Africa, the requirement for written informed consent to be obtained from staff providing information was waived by the ethics committee.

Results {#sec010}
=======

Anticoagulation services included in this audit are described in [Table 1](#pone.0227458.t001){ref-type="table"}. The number of patients receiving warfarin ranged from 30 to 800 patients per month. Specialists or medical doctors were present in all clinics except for the secondary level service in South Africa, which was staffed by nurses. All facilities had an onsite pharmacy dispensing warfarin. At the Ugandan clinics, warfarin stock outs occurred frequently.

10.1371/journal.pone.0227458.t001

###### Characteristics of the five outpatient anticoagulant services in Uganda and South Africa.

![](pone.0227458.t001){#pone.0227458.t001g}

                                                              UGANDA                                     SOUTH AFRICA                                                                                                      
  ----------------------------------------------------------- ------------------------------------------ --------------------------------------------------- -------------------- ---------------------------------------- ------------------------------------------
  **Level of care of clinic/s providing warfarin**            Tertiary Hospital                          Tertiary Cardiac Centre                             Secondary            Tertiary                                 Primary
  **Service providers**                                       Specialist; Nurse; Medical Officer         Specialist; Nurse; Medical Officer                  Nurse                Specialist; Medical Officer              Nurse; Medical Officer
  **Clinic days per week**                                    1                                          5                                                   4                    5[\*](#t001fn002){ref-type="table-fn"}   1
  **Patients per month**                                      30                                         400                                                 800                  105                                      113
  **Onsite pharmacy**                                         Yes                                        Yes                                                 Yes                  Yes                                      Yes
  **DOACs available**                                         No                                         Yes (rivaroxaban)                                   No                   No                                       No
  **INR turnaround time (days)**                              1[\*\*](#t001fn003){ref-type="table-fn"}   0 [\*\*\*](#t001fn004){ref-type="table-fn"}         0                    0 to 1                                   2[\*\*](#t001fn003){ref-type="table-fn"}
  **INR testing cost to patient per visit (GBP)**             GBP 4                                      GBP 4 (laboratory INR) GBP 1 (point of care test)   No cost to patient   No cost to patient                       No cost to patient
  **Frequency of follow-up for clinically stable patients**   Monthly                                    Monthly                                             4- to 6-weekly       Monthly                                  Monthly
  **Standard protocol used for dose adjustment**              No                                         Yes                                                 Yes                  No                                       Yes

GBP-British Pound Sterling

\*There is no dedicated INR clinic. Patients on warfarin are distributed among the specialty clinics depending on where warfarin was initiated and the indication.

\*\*No onsite INR testing services available

\*\*\*Point-of-care tests available

INR turnaround time varied (see [Table 1](#pone.0227458.t001){ref-type="table"}). At health facilities with onsite INR testing, results were available on the same day. However, for the tertiary hospital in Uganda and the primary health centre in South Africa, which did not have onsite INR testing services, INR results were returned the next day, requiring two consecutive visits for the patient. Only one site (Uganda Heart Institute) had point of care INR testing available.

At the Ugandan clinics, patients paid approximately £4 for an INR test; occasionally this fee was subsidised where point of care testing was available. Patients at both Ugandan clinics had to purchase warfarin themselves when there were drug stock-outs at the clinic; at a cost of between £3 and £6 for a month's supply of warfarin depending on warfarin dose. At the South African clinics, patients did not pay for INR testing or for warfarin.

Three of the included clinics used warfarin dose adjustment protocols. The dose adjustment protocol used at the Uganda Heart institute was based on the Modified Henry Ford warfarin maintenance dosing algorithm \[[@pone.0227458.ref011]\]. The dosing adjustment schedules used in the South African clinics were not referenced. To our knowledge these protocols had not been validated for the clinic population.

We reviewed the clinic records of 229 patients: 68 from Uganda Heart Institute, 32 from Mulago National Referral Hospital haematology clinic, 48 from Groote Schuur Hospital, 47 from Tygerberg Hospital, and 34 from Gugulethu Community Health Centre. The three most common indications for warfarin treatment were venous thrombo-embolism (49%), atrial fibrillation (32%) and valvular heart disease (including mechanical heart valves) (13%). Characteristics of included patients are summarised in [Table 2](#pone.0227458.t002){ref-type="table"}. We found that 126 patients (55%) had at least one concomitant medication which could potentially interact with warfarin \[[@pone.0227458.ref010]\]. There were 12 patients (5.2%) on efavirenz and one patient (0.43%) on lopinavir-ritonavir.

10.1371/journal.pone.0227458.t002

###### Characteristics of patients attending five outpatient anticoagulation services in Uganda and South Africa.
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                                                                          Uganda (n = 100)                                         South Africa (n = 129)                                  Overall (n = 229)
  ----------------------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------- ----------------------
  Age in years (median \[IQR\])                                           57 \[43 to 67\]                                          56 \[42 to 65\]                                         56 \[43 to 66\]
  Female (n, (%))                                                         69 (69%)                                                 87 (67%)                                                156 (68%)
  Indication for warfarin (n, (%))[\*](#t002fn002){ref-type="table-fn"}   VTE: 63 (63%)                                            VTE: 49 (38%)                                           VTE: 112 (49%)
  AF: 36 (36%)                                                            AF: 38 (29%)                                             AF: 74 (32%)                                            
  VHD: 1 (1%)                                                             VHD: 29 (22%)                                            VHD: 30 (13%)                                           
  Other: 0 (0%)[\*\*](#t002fn003){ref-type="table-fn"}                    Other: 17 (13%)[\*\*](#t002fn003){ref-type="table-fn"}   Other: 17 (7%)[\*\*](#t002fn003){ref-type="table-fn"}   
  Number of INR tests in 6 months (median \[IQR\])                        3 \[3 to 4\]                                             5 \[3 to 6\]                                            4\[3 to 6\]
  HIV-positive (n, (%))                                                   20 (20%)                                                 7 (5%)                                                  27 (12%)
  Current tuberculosis (n, (%))                                           1 (1%)                                                   1 (1%)                                                  2 (1%)
  Five most common non-communicable comorbidities (n, (%))                HPT: 29 (29%)                                            HPT: 71 (55%)                                           HPT: 100 (44%)
  HF: 10 (10%)                                                            DM: 21 (16%)                                             DM: 25 (11%)                                            
  HHD: 8 (8%)                                                             IHD: 20 (16%)                                            IHD: 23 (10%)                                           
  DCMO: 6 (6%)                                                            Dyslipidaemia: 19 (15%)                                  HF: 20 (9%)                                             
  DM: 4 (4%)                                                              HF: 10 (8%)                                              Dyslipidaemia: 19 (7%)                                  
  Ten most commonly used concomitant medicines (n, (%))                   Furosemide: 43 (43%)                                     Paracetamol: 59 (46%)                                   Furosemide: 90 (39%)
  Spironolactone: 21 (21%)                                                Enalapril: 50 (39%)                                      Paracetamol: 59 (26%)                                   
  Bisoprolol: 19 (19%)                                                    Simvastatin: 49 (38%)                                    Enalapril: 52 (23%)                                     
  Digoxin: 16 (16%)                                                       Furosemide: 47 (36%)                                     Simvastatin: 50 (22%)                                   
  Lamivudine: 15 (15%)                                                    Tramadol: 45 (35%)                                       Tramadol: 45 (20%)                                      
  Amlodipine:15 (15%)                                                     Atenolol: 32 (25%)                                       Amlodipine: 44 (19%)                                    
  Telmisartan: 12 (12%)                                                   Amlodipine: 29 (22%)                                     Atenolol: 38 (17%)                                      
  Sildenafil: 10 (10%)                                                    Hydrochlorothiazide: 26 (20%)                            Hydrochlorothiazide: 35 (15%)                           
  Efavirenz: 9 (9%)                                                       Carvedilol: 22 (17%)                                     Spironolactone: 31 (14%)                                
  Hydrochlorothiazide: 9 (9%)                                             Metformin:17 (13%)                                       Carvedilol: 29 (13%)                                    
  Zidovudine: 9 (9%)                                                                                                                                                                       

AF, atrial fibrillation; DCMO, dilated cardiomyopathy; DM, diabetes mellitus; HF, heart failure; HHD, hypertensive heart disease; HPT, hypertension; IHD, ischaemic heart disease; VHD, valvular heart disease; VTE, venous thrombo-embolism.

\* More than one indication may exist; therefore, totals may exceed 100%.

\*\*Other: included chronic venous insufficiency, antiphospholipid syndrome, thrombophilia, congenital heart block and thrombotic syndrome

TTR was suboptimal at all included sites (see [Fig 1](#pone.0227458.g001){ref-type="fig"}). Median TTR overall was 41% (interquartile range 14% to 69%).

![Time in therapeutic INR range (TTR) of patients attending five anticoagulation clinics in Uganda and South Africa (box represents median and interquartile range).](pone.0227458.g001){#pone.0227458.g001}

Discussion {#sec011}
==========

This evaluation, which included outpatient clinics managing patients on warfarin at primary, secondary and tertiary level, found that TTR was suboptimal at all included sites. This occurred despite regular INR monitoring.

Unfortunately, our findings complement other recent sub-Saharan studies in South Africa, Namibia and Botswana, all reporting poor INR control, with mean/median TTR ranging from 29% to 47% \[[@pone.0227458.ref001],[@pone.0227458.ref012],[@pone.0227458.ref013]\]. It is known that a higher TTR is associated with increased efficacy of warfarin and reduction in bleeding complications \[[@pone.0227458.ref014]\]. In patients with non-valvular AF receiving warfarin, there is a three-fold risk of ischaemic events with under-anticoagulation and a five-fold risk of bleeding events with over-anticoagulation, compared to being within the therapeutic range \[[@pone.0227458.ref014]\]. Maximising TTR is therefore crucial for attainment of good clinical outcomes, as shown by a study in the UK, where a 10% increase in time out of range was associated with a 29% increased risk of mortality, a 10% increased risk of ischemic stroke, and 12% increased risk of other thromboembolic events \[[@pone.0227458.ref015]\].

A number of factors may affect INR control. We found that INR testing was generally available at all sites; however, patients at the Ugandan clinics had to pay up to £4 for a laboratory INR test. In addition, frequent pharmacy stock outs of warfarin at these clinics means that patients also have to incur costs of privately purchasing warfarin. These costs may be prohibitive, particularly in the Ugandan population where the average household monthly income is £62 - £144 \[[@pone.0227458.ref016]\]. However, TTR was poor at South African anticoagulation services as well, despite patients not having to pay for INR testing or warfarin.

Laboratory turnaround time at two clinics was at least one day requiring a second visit for dose adjustment, also contributing to increased transport costs and missed work days. Thus, strengthening laboratory facilities and pharmaceutical supply chain and provision of near-patient INR testing may contribute to improved anticoagulation control. However, TTR was poor even at facilities with onsite INR testing and no problems of drug stock outs, suggesting that there are other factors contributing to poor TTR.

Our population had a high burden of comorbidities such as heart failure and diabetes, which may be associated with lower TTR \[[@pone.0227458.ref017]\], because of polypharmacy as well as physiological changes due to comorbidity \[[@pone.0227458.ref018]\]. In addition, high HIV prevalence may further complicate warfarin dosing due to drug-drug interactions with non-nucleoside reverse transcriptase inhibitors and protease inhibitors \[[@pone.0227458.ref019],[@pone.0227458.ref020]\]. Although our sample included few TB patients, it is important to consider that rifampicin, which is used in first-line TB treatment, induces warfarin metabolism, which further complicates warfarin dosing \[[@pone.0227458.ref021]\].

Pharmacogenomic differences due to polymorphisms in *VKORC1* and *CYP2C9* genes and additional polymorphisms in other genes e.g. *CALU* rs339097 may affect dosing requirements in patients of African descent \[[@pone.0227458.ref022]\]. Patients managed using genotype guided dosing algorithms in high-income settings have been shown to have higher mean TTR and fewer episodes of excessive anticoagulation compared to usual dosing \[[@pone.0227458.ref008]\]. Further studies need to be conducted in our population to develop and evaluate clinical and genetic dosing algorithms relevant for low-income settings.

DOACs require less frequent monitoring and are non-inferior or even superior to warfarin in preventing stroke in non-valvular AF \[[@pone.0227458.ref023],[@pone.0227458.ref024]\]. However, their access is severely limited in resource-limited settings due to cost limitations; necessitating urgent improvements in warfarin management.

This study has limitations. We only included urban sites, and findings may not be generalizable to rural settings in South Africa and Uganda. However, in Uganda, we included the clinics known to manage the majority of patients receiving warfarin anticoagulation. It is possible that there are additional challenges facing anticoagulation services in more remote and poorly resourced settings in both South Africa and Uganda, which we have not captured. We audited each included facility at a single timepoint.

In conclusion, in the South African and Ugandan clinics that we evaluated, TTR was suboptimal. Strategies to improve INR control in sub-Saharan patients taking warfarin are urgently needed as the alternative DOACs are not freely available. The findings from our work will inform further research to develop and validate a warfarin dosing algorithm, one such strategy which may improve TTR, for use in this setting.

Supporting information {#sec012}
======================

###### Data collection form.

(PDF)

###### 

Click here for additional data file.

###### 

(XLSX)

###### 

Click here for additional data file.

Thank you to the staff of Mulago National Referral hospital, Uganda Heart Institute, Groote Schuur Hospital, Tygerberg Hospital, and Gugulethu Community Health Centre for their help and support during the data collection for this work.
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